The IPO came at $83, above its range, and is set to trade today. Ardent's top owner sold at 18.3% below the last close. Aytu's buyer agreed to pay a 51.7% premium.

THE NUMBER

51.7%.

That is the premium a drugmaker backed by Inflexion agreed to pay for Aytu. It is measured against Aytu's Nov. 13 close. The buyer, Rosemont, agreed to pay $2.70 a share in cash. That values Aytu at about $56 million. There is no financing condition. Aytu closed Wednesday at $2.66, just under the offer.

A private buyer agreed to pay up to take a small public company off the market.

PREMIER FEATURE

Elon's Next THREE Moves Could Double Your Money

Musk walked away from the biggest IPO in history with a massive "war chest."

Now he's spending it...

He's already purchased a $40 billion AI firm. And a $1 billion turbine company.

But to complete his monopoly on the space economy, he still needs to acquire three specific companies. Each is publicly traded and still under the radar.

Get positioned before he moves... and you could see 100% overnight gains.

Click here for the full story.

THE SETUP
  • Fed minutes show a bigger hike was floated in October. A couple of officials said a hike above a quarter point could be weighed if inflation data came in hot. The 10-year yield closed Wednesday near 5.07%. CME FedWatch puts the odds of a quarter-point hike in December near 90%. Higher rates make buyouts cost more to fund.
  • Palo Alto Networks agreed to buy Applied Compute, an AI firm, for $4.5 billion in stock. It also raised its sales forecast for the year. Its stock was up about 9% after hours.
  • Nvidia (NVDA) was up about 2.2% before dawn after five straight losses. Walmart reports before the open.
PMD Signal Tracker

FROM OUR PARTNERS

Free Stock Pick: The Company First in Line

for America’s New Super Fuel

The U.S. Army and Department of Energy are about to flip the switch on a revolutionary new fuel — and one obscure defense contractor has a five-year head start on every competitor.

This joint, high-priority initiative — ordered by President Trump — is called Project Janus.

And the first powerplant to run this new fuel is expected to go live before December 18, 2026…

When it does, this company’s name will be everywhere.

Full details — including the name and ticker symbol — are being revealed for free.

Click HERE to get the stock name, ticker, and the full Project Janus story for free.

IN FOCUS

Anthropic Priced Above Its Range. Chip and Cloud Companies Are Set to Buy $26 Billion More.

Anthropic priced its IPO at $83 a share Wednesday. The range had been $70 to $78. The deal grew to 980 million shares, from 825 million. Its co-founders are selling about 23.6 million of them, FM reported. At $83, the whole deal comes to about $81.3 billion. The stock is set to trade on Nasdaq today as ANT.

Demand ran ahead of the deal. Anthropic's IPO drew orders for nearly seven times the shares on offer, Bloomberg reported before pricing, when the deal was 825 million shares. Those orders were indications, not allocations. CNBC put the fully diluted value at about $1.5 trillion. At the top of the old range it was about $1.4 trillion.

A separate $26 billion sale of non-voting stock would also be at $83, if it closes. Google and Nvidia agreed to buy about $10 billion each. AMD, Broadcom, Micron, Microsoft and TSMC agreed to take the rest. The cash would go to a company with big bills ahead. It has about $900.9 billion of commitments with partners for computing and infrastructure, mostly through 2045. About $70.7 billion falls due in the year after Sept. 30. It held $95.6 billion in cash and $36.3 billion in short-term investments at Sept. 30, its filing showed.

The First Public Price Is In. The First Trade Is Next.

For venture and growth holders, $83 is the first public price. The chip and cloud companies in the placement would pay the same price if it closes. The order book showed interest, not money, so trading is the real test. Trading today and in the weeks ahead will show if buyers value it above or below $83.

SIGNALS IN MOTION

SIGNAL 1: Ardent's Largest Holder Sold at an 18% Discount. Ardent Is Buying Back Part of It.

Ardent Health's largest holder sold stock at $14.50 a share. That was 18.3% below Tuesday's close. The seller is an arm of Equity Group Investments. An arm of Ventas sold a smaller slice. Ardent gets none of the money. It will buy back 1.5 million shares with its own cash, at about $13.70 each.

The final filing shows Equity Group's stake falling from 54.8% to 50.3%. The sellers agreed not to sell more for 90 days. The stock closed Wednesday at $14.40, a dime under the sale price.

WHAT RESOLVES THIS

For sponsors with listed stakes, this put a price on selling to public buyers. The price was 18.3% below the last close, set Tuesday night. That came after the stock rose about 101% this year through Tuesday. Equity Group's next sale after the lock-up will show if big holders still pay that much to sell.

SIGNAL 2: Vitruvian Agreed to Buy Into IGEL at a Value Above $1 Billion. TA Is Staying In.

Vitruvian Partners' funds agreed to invest in IGEL at a value above $1 billion. IGEL makes software that guards work computers. TA has backed it since 2021 and will stay in. The deal is expected to close early next year.

IGEL said its yearly recurring revenue grew more than 40%. The size of Vitruvian's stake was not given. Nor was whether TA sold any shares, or whether IGEL got new cash.

WHAT RESOLVES THIS

For growth investors, a pending private deal valued IGEL above $1 billion without a listing. TA stays in while a new investor sets the price. Outsiders cannot yet tell whether TA took money off the table. Closing terms, or a disclosed stake, would show it.

SIGNAL 3: TPG Is Reported to Be Days From a Deal for BILL. No Price Has Surfaced.

TPG is close to a deal to take BILL Holdings private, the FT and Reuters reported Tuesday. Reuters, citing a source, said a deal could come within days at a premium. Neither company has confirmed talks.

BILL shares jumped 12.6% Tuesday and rose again Wednesday. No merger filing had appeared by early Thursday.

WHAT RESOLVES THIS

For buyout investors, BILL's price moved before any bid was known. The stock rose about 14.5% in two days with no price on the table. That run could reverse if no deal is signed. A signed agreement filed with the SEC would set the price and the premium.

PARTNER SPOTLIGHT

Why Most Accounts Blow Up in One Trade

It's rarely a slow bleed. It's usually one trade that was too big, held too long, hoping it would come back.

My Safe Trade Options Formula gives you 5 checks to run before that trade ever happens.

Normally $29.97. Free through this link.

Protect your account.

WHAT MOST WILL MISS
THE CROSSOVER

Private Market Trends Driving Public Market Moves

Anthropic Priced Above Its Range. Ardent's Holder Sold at a Discount.

Two very different prices were set this week. Anthropic priced at $83, above its range. Ardent's largest holder sold stock at 18.3% below the last close. A private buyer agreed to pay a 51.7% premium to take Aytu off the market. TPG is reported to be near a deal for BILL at a premium. Our read is that public buyers charge sellers for size and pay up for what they cannot get elsewhere. Anthropic's first trades, and Ardent's next sale after the lock-up, would test that read.

On the calendar...

When

Event

Thu., Nov. 19

Anthropic expected to begin trading; Walmart reports before the open; Philadelphia Fed survey, 8:30 a.m.; HarbourVest Global Private Equity tender closes

Fri., Nov. 20

Anthropic offering expected to close

Wed., Nov. 25

October PCE price index

Around Dec. 1

Aytu tender offer expected to start

T/W, Dec. 8-9

Fed meeting

$144 million.

That’s what Sanofi has paid one AI drug company so far.

See which one (free) →